Loading...
Market
First global distribution partner for Merck's clesrovimab?
2
Resolution / Starting Odds
Pfizer • 25%
Johnson & Johnson • 25%
Sanofi • 25%
Other • 25%
Official announcements from Merck or the partnering company
Story
Merck's Clesrovimab Shows 60.4% Efficacy in Preventing RSV in Infants
Oct 17, 2024, 10:02 PM
Merck's investigational monoclonal antibody, clesrovimab (MK-1654), has demonstrated significant efficacy in reducing the incidence of respiratory syncytial virus (RSV) disease and hospitalization in healthy preterm and full-term infants. The experimental therapy showed a 60.4% effectiveness in reducing RSV infections in infants, according to data released by Merck. This positive outcome paves the way for potential approval of clesrovimab as a preventative treatment for RSV in infants.
View original story
Similar markets
Yes • 50%
No • 50%
Roche • 25%
Pfizer • 25%
AstraZeneca • 25%
No new partnership • 25%
Pfizer • 25%
Roche • 25%
Novartis • 25%
Other • 25%
Yes • 50%
No • 50%
Pfizer • 25%
Moderna • 25%
Johnson & Johnson • 25%
Other • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Roche • 25%
Other • 25%
Yes • 50%
No • 50%
Pharmaceutical company • 25%
Research institution • 25%
Healthcare provider • 25%
No new partnerships • 25%